Fast Accurate Point of Care COVID-19 Pandemic Diagnosis Enabled Through
  Advanced Lab-on-a-Chip Optical Biosensors: Opportunities and Challenges by Asghari, Aref et al.
   
 
   
 
1 
 
Fast Accurate Point of Care COVID-19 Pandemic 
Diagnosis Enabled Through Advanced Lab-on-a-Chip 
Optical Biosensors: Opportunities and Challenges  
 
Aref Asghari1, Ϯ, Chao Wang1, Ϯ, Kyoung Min Yoo1, Ϯ, Hamed Dalir1, 2, * and Ray T. Chen1, 2, * 
 
1Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX 78758, USA. 
2Omega Optics, Inc. 8500 Shoal Creek Blvd., Austin, Texas 78757, USA 
 
 
* Corresponding Authors Emails:  hamed.dalir@omegaoptics.com , chenrt@austin.utexas.edu 
Ϯ These authors have equal contributions to this work. 
 
Abstract 
 
The sudden rise of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic early 2020 throughout the world has called into drastic action measures to 
do instant detection and reduce the spread rate. The common diagnostics testing 
methods has been only partially effective in satisfying the booming demand for fast 
detection methods to contain the further spread. However, the point-of-risk accurate 
diagnosis of this new emerging viral infection is paramount as simultaneous normal 
working operation and dealing with symptoms of SARS-CoV-2 can become the norm 
for years to come. Sensitive cost-effective biosensor with mass production capability is 
crucial throughout the world until a universal vaccination become available. Optical 
label-free biosensors can provide a non-invasive, extremely sensitive rapid detection 
technique up to ~1 fM (10-15) concentration along with few minutes sensing. These 
biosensors can be manufactured on a mass-scale (billions) to detect the COVID-19 viral 
load in nasal, saliva, urinal, and serological samples even if the infected person is 
asymptotic. Methods investigated here are the most advanced available platforms for 
biosensing optical devices resulted from the integration of state-of-the-art designs and 
materials. These approaches are including but not limited to integrated optical devices, 
plasmonic resonance and also emerging nanomaterial biosensors. The lab-on-a-chip 
platforms examined here are suitable not only for SARS-CoV-2 spike protein detection 
but also other contagious virions such as influenza, and middle east respiratory 
syndrome (MERS). 
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I. INTRODUCTION 
A. Importance of highly sensitive point of care detection 
          The Corona virus disease 2019 (COVID-19) pandemic and its rapid growth rate has 
driven an unprecedented worldwide demand for measures to mitigate its fast spread rate1–3. 
Adding mandatory large-scale policies like social distancing and extreme antiviral 
disinfection measures and protocols in coping with infected patients, it becomes paramount 
to have detection and curing system developed in a catastrophic crisis state of which very 
few mankind alive have experienced before.  It is a commonly held view that pressures of 
war have stimulated advances in engineering, science, and medicine.  Therefore, the new 
invisible battle against SARS-CoV-2 virus infection can stimulate major breakthroughs in 
the development of diagnosis and treatment systems.  SARS-CoV-2 highly contagious 
infection is hard to detect as patients can be present with clinically inapparent symptoms 
including fever, cough, or shortness of breath4.  The worldwide morbidity and mortality of 
SARS-CoV-2 plus no available vaccine or guaranteed treatments on the horizon as of mid-
2020 bolds the necessity for researchers to probe various medical interventions. Immediate 
cost-effective point-of-risk measures like identification, diagnosis and isolation of the 
infected individual is still regarded as the single best viable solution to slow down 
this pneumonia pandemic.  
 
B. Structure of the SARS-CoV-2   
 SARS-CoV is an enveloped, single stranded RNA virus, that exists in humans and animals, 
and is mainly transmitted through aerosols and nearby interpersonal contacts 5,6.  Once the virus 
enters the body, it sticks to primary target cells which provides plenty of virus receptors, the 
angiotensin-converting enzyme (ACE2) 5,7. Its genome RNA infusion into the cell results in 
the formation of protein building blocks consist of spike, envelope, membrane, nucleocapsid, 
and proteins8–10. Thus, human SARS-CoVs relies heavily on ACE2 for infusion into the target 
cell for which S glycoprotein trimeric spikes on the surface mediates the entrance into the host 
cell11. The S glycoprotein of SARS-CoV is therefore the main target for neutralizing antibodies 
(nAbs) 12. Similar SARS-CoV and SARS-CoV-2 amino acid identity in their S proteins makes 
them prone to have analogous Immunogenic surfaces on these antigens13. Coronaviruses 
demonstrate a complex pattern for receptor recognition7,14,15 (Figure 1.c). The attempts to block 
the infusion of virus has been carried out through targeting mainly spike protein of SARS-
CoV-2 and the receptor binding domain (RBD). Antibodies developed specifically for these 
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regions can expand the potency and power and chance of success against the infusion of SARS-
CoV-2 in the host cell. Once the virus enters the body through the cells, it replicates and virions 
are then set free to infect new target cells16,17. SARS Infectious viral particles can be found in 
respiratory secretions, urine and sweat. SARS-CoV infection harms lung tissues resulting in 
pneumonia with rapid respiratory deterioration and failure and in almost %5 of cases, death18,19. 
Development of effective vaccine against SARS-CoV-2 can be effectively applied through S 
protein and especially the receptor binding domain (RBD) as they induce highly potent 
neutralizing antibody to block virus binding and its membrane infusion or forming immunity 
protective layer against viral infection5. 
 
   
 
   
 
5 
 
   
 
   
 
6 
Fig 1. (a) Colorized schematic picture depicting a heavily infected lung by SARS-COV-2 virus   molecules. SARS-
COV-2 molecular structure is illustrated in detail as well:   the RNA and membrane protein are significant as they 
provide great affinity   to bio receptors functionalized on the surface of biosensor. (b) (A) Life cycle of pathogenic 
human SARS-CoVs.  The virus enters the target cell through   respective cellular receptor angiotensin-converting 
enzyme 2 (ACE2) on the   membranes of host cells. Viral genomic RNA is then unveiled in the cytoplasm and 
translated into viral polymerase proteins. Viral RNA and nucleocapsid (N) structural protein are replicated and 
transcribed in the cytoplasm to form a mature virion, then released from host cells 12. (c) The virus enters the target 
cell by first   binding its S glycoproteins to the respective cellular receptor   angiotensin -converting enzyme 2 
(ACE2) on the membranes of host cells which   mediate virus-cell membrane fusion and viral entry, (left) Schematic 
of SARS-CoV-2 virus binding to ACE-2   receptors on a human cell (right) Schematic shows the coronavirus spike   
protein (red) mediates the virus entry into host cells. It binds to the   angiotensin converting enzyme 2 (blue) and 
fuses viral and host membranes. 
 
C. Detection mechanisms for SARS-CoV-2 viral infection  
The most standard procedure for identifying pathogens like SARS-CoV-2 relies on real-time  
reverse transcription- polymerase chain reaction (RT-PCR) in which the virus ribonucleic 
acid (RNA) molecules (Fig. 1) go through a time consuming labeling procedure known as 
reverse transcription (RT) 20.  For patients who present late with a viral load   below the 
detection limit of RT-PCR assays, serological diagnosis with less sensitivity is also used. 
The aforementioned process and similar clinical diagnosis requires advanced laboratories, 
equipment and expertise hard to be found in under-developed remote areas that are more 
prone to the outbreak20–24. 
The test is done for a qualitative analysis of nucleic acid from the SARS-CoV-2 gathered from 
people who meet SARS-CoV-2 virus clinical infection signs and symptoms (Fig 1.b). It has 
also been reported that SARS-CoV-2 can be clinically detected from saliva, blood, and urine 
samples in 30 to 45 minutes. Considering the high cost and time-consuming nature of clinical 
diagnosis procedure like RT-PCR (minimum 3 hrs25) and test kit requiring samples generated 
by urine, saliva, blood and nasopharyngeal swabs (minimum 30 minutes9–11), the need to 
develop a fast-accurate detection method for SARS-CoV-2 is better recognized. Biosensors 
can provide the next best alternative reliable solution to clinical diagnosis with much faster 
real-time detection without compromising sensitivity and accuracy29,30. Optical biosensors are 
particularly likely to become the future COVID-19 diagnostic tools31–35. By exploiting the 
strong light-matter interactions, one can create an ultra-sensitive label-free real-time detection 
platform for novel SARS-COV-2. Primarily, an optical biosensor translates the capture of the 
target analyte in a measurable alteration of a light property, such as refractive index (RI), 
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intensity or resonance shift, through different methods such as resonators and interferometers 
(Fig. 2). 
        However, due to time-sensitivity and shocking nature of the COVID-19 pandemic, 
early efforts for detection have been mainly based on how existing systems can be integrated 
together competently to outperform the existing processes in respect to sensitivity and time-
consumption.   It has been demonstrated by Chen et al. and Alam et al. 36,37 that deep learning 
methods can be efficiently used to aid radiologists in real-time accurate diagnosis of 
COVID-19 infection from computed tomography (CT) images. Artificial intelligence (AI) 
technology have been implemented to thoroughly process a large group of patient 's 
characteristics by four different algorithms to come up with the 18 diagnostic factors relating 
to COVID-1938.  Zhang et al. reported the use of graphene field effect transistors (FETs) in 
combination with selective antibodies to develop coronavirus immunosensors39.  
Combination of plasmonic photothermal effect and localized surface plasmon resonance 
sensing transduction has also been proposed as promising for COVID-19 diagnosis29. 
 
D. Principle of lab-on-a-chip optical biosensors  
         To spot and monitor the real-time binding of small numbers of biomolecules such as 
proteins, biosensors with ultra-high sensitivity are required.  
 
Fig 2. Schematic working principle of a lab-on-a-chip (LOC) optical biosensor.  
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          Optical transducers have been extensively researched, commercialized and deployed in 
hospitals. Label-free optical biosensing can provide sensitive and durable point-of-care testing 
(POCT) device which is imperative for SARS-CoV-2 epidemic containment as it also can be 
easily operated at the point-of-risk by individuals without specialty training40 (Fig. 2). On top 
of that, label-free optical biosensors have exhibited a strong conceivable potential to grow 
expeditiously in healthcare and biomedical fields as they provide a condensed accurate 
analytical tool to promote mass-scale screening of a broad range of samples through different 
parameters35,41,42. Optical biosensing does work in different physical transduction principles 
such as interferometers, resonators and plasmonic43 and has been investigated to monitor many 
viruses with a good accuracy in different studies31,44,45. 
E. Surface functionalization strategies 
        The difficulty of measuring physical features of biological analytes in a biosensor has led 
to label-based techniques in which an additional molecule is attached to immobilized target 
molecules, viruses, or cells to enhance quantitative signal41. In a typical biosensor, the specific 
bioreceptors are immobilized on the chip sensing area to detect the targeted pathogens or 
proteins. Only the target biomolecules will be bounded to their corresponding biomolecular 
receptor upon introduction of analytes into the sensing area. 
Notable examples of labels used in biosensing are dye molecules, a fluorescent tag, or enzyme. 
Various types of bioreceptors-targets coupling mechanisms have been also demonstrated in Fig 
3 including antibody-antigen binding, enzyme-substrate catalytic reaction and cDNA-DNA 
hybridization. These labels require sophisticated reagent selection and modification that in turn 
come with the drawback of perturbing the assay and making final detection a challenging task. 
On top of that, labeling chemistry is both expensive and time-consuming. Thus, recent 
development in biosensing systems have been more intrigued by unlabeled or unmodified 
biomolecules (label-free biosensing)35,41,46,47in which native molecular properties like 
molecular weight and RI are utilized for sensing. Label-free detection does have its own 
shortcomings for example, it requires low non-specific binding43 and sufficient signal to be 
generated upon targets binding35.  However, its benefits such as providing real time analysis 
by simplifying assays and reducing time and number of steps required as well as eliminating 
experimental uncertainty far exceed its limitations48.   
         The sensing transduction signals in Optical label-free biosensing platform functions 
based on miniscule changes in refractive index resulting from the attachment of biomolecules 
to the immobilized bioreceptors. It is of vital importance to have a highly sensitive 
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biorecognition layer on the transducer surface in a label-free optical biosensors43,49,50. It goes 
without saying that the biosensor final sensitivity and specificity is strongly dependent on the 
immobilized molecules and the accessibility of target analytes to them. Therefore, the 
optimization of sensing surfaces and their biofunctionalization strategies is a significant factor 
for an accurate label-free optical biosensor where the sensitivity and accuracy are highly 
necessitated43. 
 
Fig. 3. Various receptors-targets coupling mechanisms on the biosensor surface showing (a): Antibody-
Antigen binding b) Enzyme-surface catalytic reaction c) DNA hybridization d) schematic of SARS-CoV-2 
virus binding to ACE2  receptors on a human cell (Inset shows the coronavirus spike protein (red) mediates 
the virus entry into host cells. It binds to the angiotensin converting enzyme 2 (blue) and fuses viral and host 
membranes). 
 
    The diverse range of target molecules and biosensor applications make it extremely 
difficult for a universal surface biofunctionalization procedure to be obtainable; hence, the 
procedure needs to be custom designed consequently. In a graphene-based Field Effect 
Biosensing(FEB), the surface is functionalized for protein immobilization with anti-Zika NS1 
mouse mAb 6B1 developed by the Centers for Disease Control and Prevention51. Polyethylene 
glycol (PEG) has been studied particularly for removing proteins from the surface of silicon 
based biosensors as it provides a stable and anti-absorptive block against undesired non-
specific interactions52,53. Detection of specific antibodies directed to viruses such as SARS-
CoV-2 is another choice of identification for spotting infection. It is widely accepted that 
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immunoglobulin M (IgM)and G (IgG) provide the first line of defense during viral infections27. 
However, it has been shown that for SARS infections, the IgM and IgG antibody could be 
detected in patients’ blood after 3–6 and 8 days, respectively. Thus, targeting antibodies is not 
a suitable method for screening early cases of COVID-19. Detection of COVID-19 viruses in 
the range of picomolar (pM) to attomolar (aM) concentrations are possible if the biosensor 
provides a sensitivity range of 10−6 ~ 10−7 refractive index units (RIUs). Slow light-based 
biosensors are tremendously sensitive to refractive index variations and can determine the 
interactions with receptor biomolecules with the pM level. Most commercially available 
POCTs like home-use pregnancy and influenza test are based on immunostrips with the 
sensitivity level of nanomolar54. Both observation of the resonant shift or the reflectivity 
change will fulfill the requirement of the sensitivity. 
           The two-dimensional AuNIs functionalized with cDNA receptors (RdRp-COVID-C) 
can perform a selective detection of the RdRp-COVID through DNA hybridization29. The 
surface functionalization of sensor surfaces has resulted in sensitivity improvement and 
suppressing the nonspecific bindings29. The virus-like particle absorption has resulted in more 
SPR peak shift on non-functionalized surfaces compared to functionalized one simply as there 
are a greater number of adsorption sites on it53.  
Different structures have their own advantages and disadvantages. Elisa-based sensing requires 
additional secondary binding anti-body usage while it limits the application for fast detection 
requirements.  
II. INTEGRATED OPTICAL BIOSENSORS 
         Here, we explore the most well-defined bio-photonic sensing mechanisms based on 
functionalized waveguides, interferometer, and resonance shift in microcavities. 
A. Evanescent wave sensing: refractive index and absorption variation  
         Due to its immunity to electromagnetic interference (EMI), compactness and high 
selectivity, optical waveguides have attracted special attention as a basic biosensing 
system55,56. The interaction of target molecules with bioreceptors on the surface leads to 
effective index and absorption coefficient change (Fig. 4 (a)). The effective index change or 
loss change is a function of the concentration of biological or chemical targets on the surface. 
Effective mode index change for a perturbed waveguide can be calculated through the variation 
method47: 
Δ𝑛𝑒𝑓𝑓 =
𝑛𝑚
2 −𝑛𝑐
2
𝑍0𝑃
∬|𝐸(𝑥, 𝑦)|2𝑑𝑥𝑑𝑦                              (1) 
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where 𝐸(𝑥, 𝑦) is the electric field, 𝑍0 is the free space impedance and 𝑃 represents the light 
wave power, 𝑛𝑐 and 𝑛𝑚  are the refractive indexes of the aqueous solution without analyte, and 
molecular adsorption layer, respectively. 
          The vertical distance from the interface z does reduce the strength of the evanescent 
electric field exponentially. The penetration depth (d) can be calculated from the incident 
wavelength (λ) and incident angle (𝜃) using the following formula: 
𝑑 =  
𝜆
4𝜋 √𝑛0𝑠𝑖𝑛2𝜃 −𝑛1
2 
                 (2) 
          Sensitivity (S) and limit of detection (LOD) are the two main criteria for evaluating the 
performance of the evanescent field sensor, which in turn depends on the strength of the 
interaction between the substance and light in a solution or on the surface56.  In waveguide-
based sensors, the expression of surface sensitivity (𝑆𝑊𝐺)  is defined by the change in the 
effective refractive index (𝜕𝑛𝑒𝑓𝑓)  of the surface vis-a-vis the change in the additional layer of 
thin molecules (𝜕𝜌): 
                                 𝑆𝑊𝐺 =
𝜕𝑛𝑒𝑓𝑓
𝜕𝜌
                                                                                 (3) 
     The surface sensitivity to specific target molecules is not suitable for general 
comparisons between sensors operating with different biosensing assays. 
Figure 4 illustrates several different types of typical waveguide-based biosensors. Surface 
perturbation will cause change in absorption coefficient, which can be monitored in the output 
intensity (I) of waveguide. Optical waveguides have been extensively explored in different 
platforms including, but not limited to, rectangular waveguides57, tapered fibres58 and more 
sophisticated structures such as photonic crystal waveguides (PCW) 47,59–68, subwavelength 
grating57,69 and Bragg grating70. As shown in Fig. 4 (b), Klimant et al. integrate a sensor-based 
planar waveguide with a 460 nm light emitting diode (LED), compatible with inkjet or screen-
printing processing technologies. Correspondingly, the photodiode can be processed from the 
solution through printing technology, so that the sensor itself can be easily integrated into a 
single chip. The sensitivity of the optical sensor can be enhanced by extending the optical path. 
On the other hand, by simply depositing a gold layer, the device concept can be used for a 
surface plasmon resonance, which can improve the LOD even further71. Lear et al. reported an 
organic nanofilm based on optical waveguide biosensors (Fig. 4 (c)). The evanescent field is 
coupled to an integrated detector array that is buried beneath the waveguide. Toward the 
addition of nanofilm on the surface of the waveguide, the optical sensor exhibits a sensitivity 
of 20% modulation per nm. The device is capable of sensing multiple analytes 
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simultaneously72. Another interesting approach have been introduced by Shi et al. They 
reported a variety of analytes with integrated fluorescence based on multi-channel sensors (see 
Fig. 4d). A broad linear response range was measured; 0.36 µg/L to 2.50 µg/L with a LOD of 
0.21 µg/L is reported. This idea provides a method for measuring MC-LR in actual water 
samples73. 
 
Fig 4. (a) Schematic of a waveguide-based biosensor facilitated through biorecognition element attached on 
its surface to bond with COVID-19 molecule. (b) Side view scheme of an optical sensor. This device provides 
an easy method to couple light into the planar waveguide free from prisms or gratings. The entire sensor can be 
fabricated by inkjet or screen-printing techniques71. (c) (left) Schematic view of the array coupled biosensing 
device working based on the field localization redistribution which happens when a waveguide cross-section 
changes during the specific binding of analyte in the targeted regions (right) Photocurrents measured before (blue 
line) and after (red line) the photoresist is patterned as well as the resulting modulation ratio (green line)72. (d) 
(top-left) Photographic image of light propagation along the waveguide-based sensor and (bottom-left) A cross-
sectional view of the waveguide-based sensing, isolation layer and location of the surface chemistry (right) Using 
anti-MC-LR monoclonal antibody (MC-LR-MAb, 8C10), a linear dynamic response range of 0.36 µg/L to 2.50 
µg/L with a LOD of 0.21 µg/L is determined, crucial for measurement of MC-LR in real water samples73.  
        In order to maximize the sensitivity of the waveguide-based biosensor, the speed of 
light can be reduced even further. For this reason, the group velocity of the input pulse can 
be reduced by designing the photonic crystal structure35. Photonic crystal waveguides slow 
down the speed of light and introduce other enhancement factors, thereby enhancing 
absorption-based sensing on the surface of the waveguide. 
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B.  Integrated interferometer sensing 
          Integrated interferometer photonic is one of the most practical architectures for sensing 
applications. It is based on splitting the input beam into two arms through a Y-junction, one 
arm is completely retained as the reference arm, and the other arm contains the target. The 
interaction of electromagnetic waves on the sensing arm will cause a phase difference with 
respect to the reference arm, and recombination of the two beams in the output will cause 
constructive or destructive interference, see Fig 5 (a). 
Output intensity 𝐼𝑂𝑢𝑡 of the MZI is described as follows 
34,74,75:  
                       𝐼𝑂𝑢𝑡 = 𝐼𝑠𝑒𝑛 + 𝐼𝑟𝑒𝑓 + 2√𝐼𝑠𝑒𝑛𝐼𝑟𝑒𝑓cos (𝜑0 + Δ𝜑)                                      (4) 
where 𝐼𝑟𝑒𝑓  and 𝐼𝑠𝑒𝑛  are light intensity in reference and sensing arms, 𝜑0  is initial phase 
difference between two arms without external perturbation. The sensitivity of the MZI-based 
sensor is related to the phase sensitivity relative to the length of the sensor arm: 
                                                        𝑆𝑝ℎ =
∆𝜑
∆𝑛𝑒𝑓𝑓𝐿
                                                            (5) 
In an imbalanced MZI, considering the phase matching condition, vis-a-vis the wavelength 
sensitivity, we can approximate the phase sensitivity of the MZI-based sensor: 
                                                        𝑆𝑝ℎ =
2𝜋
∆𝜆
𝑆𝐹𝑆𝑅
𝐿
                                                           (6) 
where, ∆𝜆 is the free spectral range (FSR) and 𝑆𝐹𝑆𝑅 is the spectral sensitivity.  
 
        Chemical and biosensing via Mach-Zehnder interferometers (MZI) have been widely 
exploited76 and judicious design of imbalanced interferometers based on waveguides and 
photonic crystal waveguides explored by a lot of research groups35,59,61. Fig. 5b shows an MZI 
biosensor with a silicon nitride strip waveguide as the reference arm, and a silicon nitride slot 
waveguide as the sensing arm. Park et.al76 designed a slot waveguide in the sensing arm to 
maximize the overlap between light and target analyte (see Fig. 5c). They reported a wide range 
of linear tests with concentrations ranging77 from 19 fM to 190 nM, R2 = 0.979177. The 
asymmetry of the MZI array is used to detect miRNA in human urine samples, and its linear 
fitting curve is R2 = 0.997. Pavesi et. al78 demonstrated detection of Aflatoxin M1 
functionalized with antibody fragments. They demonstrated a volumetric sensitivity of 104 
rad/RIU, leading to a LOD below 5 × 10-7RIU (see Fig. 5d). 
As shown in Fig. 5e, Morthier et. al have shown a polymer based on a lateral bimodal 
interferometer. They used two transverse modes in the waveguide to create the interferometer. 
The overall sensitivity of the manufactured interferometer sensor with a sensing length of 5 
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mm is reported to be 316π rad/RIU, and the extinction ratio can reach 18 dB. This method is 
promising for future commercial development. However, reliability of polymer needs to be 
further studied. Figure 5g shows the schematic structure of a spatially resolved resonant 
waveguide grating (RWG) for single cell detection. The sensor consists of (1) glass substrate, 
(2) a grating part, and (3) a waveguide with high refractive index. Owing to total internal 
reflection after the light guides in the waveguide, the light propagates out of the waveguide. 
Note that the wavelength of the resonance is unique to the coupled light and is sensitive to the 
local reflection index, which is proportional to the density of the target analyte in the 
penetration depth of the biosensor. The mechanism of RWG device can be also considered in 
the resonance-based biosensors. Figure 5 h,i illustrate a bimodal waveguide (BMW) sensor. 
BMW sensor is a universal path interferometric device based on the principle of the evanescent 
field detection. When we use it in mixture with a bio-recognition element it can directly detect 
the analyte of interest. The bimodal waveguide supports two transverse modes at the center, 
while single mode waveguide forms the input and output at the two sides of the bimodal 
waveguide. Various reports have shown sensitivity up-to tens of part-per million (ppm) level 
(Fig. 5h) for gas sensing as well as bio sensing (Fig. 5 f, i). Figure 5i, shows Si3N4 surface of 
a BMW device used to enhance the performance of the biosensor. The propagation mode is 
caused by the sudden increase of the waveguide core, which changes from single-mode 
operation (150 nm) to double-peak operation (340 nm). Fundamental mode operation relies 
more on the propagating wave at the core than the excited mode. Thus, both modes are affected 
differently through their evanescent field leading to waveguide output interference because of 
biorecognition event happening on the sensor area surface. This change can provide the 
sensitivity of the system. Analogous platform with a laser-based bimodal waveguide 
interferometer is proposed to detect the COVID-19 via changes in the sensor's evanescent light 
field (Fig.5 f). 
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Fig 5. (a) Schematic diagram of MZI biosensor
76
, The MZI biosensor includes a reference arm, and a sensing arm 
connected to two Y junctions. (b) (left) An MZI biosensor with a silicon nitride strip waveguide as the reference 
arm, and a silicon nitride slot waveguide as the sensing arm, (b) (right) shows the phase change induced by 
streptavidin binding as a function of the concentration with the range of 19 fM to 190 nM
76
 which provides a 
linearity of R2= 0.9791, (c) (left) Schematic diagram of silicon nitride based on MZI77, used to detect miRNA in 
human urine samples, (c) (right) Phase change to the binding of target miRNAs with a linear fitting curve of R2= 
0.997, (d) (left) Schematics of an asymmetric MZI biosensor with purified solutions, (d) (right) Volume sensitivity 
measurements with ~ 10650 rad/RIU78, (inset) phase shift curve for an MZI biosensor with different concentration 
of solutions. (e) Schematic structure of the polymer based bimodal interferometer. A 5 mm sensing length provides 
sensitivity of 316π rad/RIU, and extinction ratio of 18 dB. (f) A novel laser-based BMW sensor proposed to detect 
the COVID-19 via alteration in the evanescent light field. (g) Schematic structure of a spatially resolved resonant 
waveguide grating for single analyte detection. Due to the total internal reflection after the light guides in the 
waveguide, the light propagates and reflects out of the waveguide. Wavelength of the resonance is proportional 
to the coupled light and is highly sensitive to the local reflection index, which is directly related to the density of 
the target analyte within the penetration depth of the biosensor. (h) Schematic of the nanoZIF-8-based BMW 
sensor with the sensitivity level of tens of ppm, and (i) Interferometric mechanism of the BMW sensor. Further 
enhancement of the sensitivity is expected by introducing the slow-light effect into BMW sensors. 
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C. Resonance shift sensing  
         Contrasted to waveguide-based sensors that rely on light wave absorption, resonant 
displacement in functionalized microcavities provides a wide range of ultra-sensitive optical 
biosensors79,80. The magnitude of binding is determined by De Feijter’s formula81 that relates 
the absolute quantity of adsorbed molecules M with the change in the refractive index as: 
      𝑀 = 𝑑𝐴
𝑛𝐴−𝑛𝑐
𝑑𝑛
𝑑𝑡⁄
                                                              (7) 
where dA is the thickness of the adsorbed layer, nA is the refractive index of adsorbed 
molecules, nC is the refractive index of cover solution and dn/dc is the change in the refractive 
index of molecules, which is proportional to the shift dλ in position of the resonance peak. The 
size of the resonance wavelength shift is proportional to the number of adsorbed biomolecules, 
thus providing a label-free method to quantitatively determine the target analyte. 
 
1. Ring Resonators 
        Although high quality (Q) ring resonators can be achieved with a larger radius, the trade-
off between the Q and the free spectral range (FSR) limits the radius for a given FSR, which 
should be large enough for effective recognition of the sensing signal from the adjacent 
interference signals or for large scale on-chip multiplexing sensing applications. Wang et al. 
82,83 proved through experiments that the Q-enhanced SWGMR was specially designed using 
a trapezoidal silicon column (T-SWGMR)( Fig 6). According to the report, the SWGMR has a 
Q of ~5600 even with a large radius of 15 μm, smaller radius provide much higher Q. 
Contrasted with conventional rectangular silicon pillars comprised of SWGMRs (R-
SWGMRs), an asymmetric effective refractive index distribution is created, which can 
significantly reduce bending loss and thus increase the Q of SWGMRs. 
      The experimental results show that the applicable Q value of T-SWGMR with a radius 
of 5 μm is as high as 11,500, which is 4.6 times the Q value (about 2800) provided by R-
SWGMR with the same radius, indicating that the propagation loss is reduced by 81.4%. To 
go one step further, Yan et al.84 proposed a T-SWGMR biosensor and demonstrated the unique 
stable surface sensing characteristics through a demonstration of miRNA detection at a 
concentration of 1 nm (Fig 6b) 
      In addition to utilizing the unique stable sensing characteristics of SWGMR and the 
enhanced Q of T-SWGMR, Chang et al. 69 showed a pedestal T-SWGMR biosensor that 
maximizes the mode volume overlap by implementing an asymmetric refractive index 
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distribution along the vertical direction on the silicon-on-insulator (SOI) platform, thereby 
further improving sensitivity( Fig 6.d). Both theoretic analysis and experimental proofs show 
that the volume sensitivity and surface sensitivity have been significantly increased by 28.8% 
and 1000 times, respectively. For streptavidin, a spectrometer with a resolution of 0.01 nm is 
used, and its LOD is about 400 fM. Owing to imperfect manufacturing process, experimental 
Q estimate of T-SWGMR with a radius of 10 μm and FSR of ~13 nm is 1800. The optimized 
SWGMR with symmetric coupling demonstrated by Huang; et al. 85 estimated Q to be 9800. 
 
Fig 6. Subwavelength grating waveguide micro-ring/racetrack biosensors, (a) High Q subwavelength grating 
waveguide ring (SWGR) resonator based on trapezoidal pillars82,83, (b) Pedestal SMGMR base biosensor for 
improved S84, (c) T-SWGMR based high Q and high S biosensor83, (d) Racetrack SMGR biosensor with high Q 
and high S69. 
 
2. Microtoroid 
         Microtoroids are resonators with a Q of >108 and a small mode volume which can be 
fabricated on silicon using standard microelectronics techniques86. However, microtoroids 
need to be strictly aligned with the tapered fiber waveguide to achieve high coupling and cannot 
meet our needs for high-throughput multiplexing sensing. Vahala; et al.86 demonstrates the 
possibility of detecting unlabeled single molecules and higher concentrations on a single 
platform (Fig 7a, b). According to reports, the quality of performing planar lithography is about 
1.83×108. The author reports that by using the IL-2 solution, the micro-ring sensor can provide 
a dose response of 10-19M to 10-6 M and a working range of 5 aM to 1 µM. In another report 
for a microtoroid with a diameter of 90 µm, authors reported87 that a measurement lifetime of 
43 ns corresponds to an inherent quality factor of 1.25×108 (Fig 7c, d). 
Slo
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Slo
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(c)
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Fig 7. The cross-sectional view of the fabricated microtoroid based biosensor
86
. (a) SEM image of 
the UHQ microtoroid optical resonator, (b) A finite element model of a 4-mm minor diameter 
microtoroid resonator surrounded by water. Note part of the field leaks into the environment (white 
arrow). This interaction between the whisper gallery mode and the environment provides ultra-
sensitive detection,(c) Measured lifetime of 43 ns
87
 corresponds to an inherent Q of ~1.25 ×108, 
(d) Microtoroid with the quality of ~1.83 × 108 and use of IL-2 solutions can provide a dose 
response of 10−19 M to 10−6 M and a working range of 5 aM to 1 µM.  
 
3. Photonic Crystal  
        For micro-cavity photonics crystal (PhC) sensors, we mainly use 2d-PhC biosensors, 
which have the advantages of design flexibility, compact size (surface area of about a few 
square microns) and strong light interaction with the analyte of interest. As shown in Fig. 8 a-
b, Chen; et al. recently confirmed the work of practical pancreatic cancer detection by using 
nanopore-assisted high-Q (22000) and high-S (112nm/RIU) L13 PhC cavities60. The detection 
results show that a concentration of 8.8 femto-molar (0.334 pg/mL) pancreatic cancer 
biomarker was successfully detected in patient plasma samples, which is 50 times more diluted 
than conventional enzyme-linked immunosorbent assay (ELISA). To go further, by designing 
and developing multimode interference (MMI) separators47,62,64–66,88, high-throughput and 
multiplexed biosensor arrays have been proposed and demonstrated, (Fig. 8 a, b47,64–66). The 
integrated scheme and array method proposed and proven improve the multi-parameter and 
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multi-function detection capabilities of the sensor and can be used in practical diagnostic 
applications. 
 
Fig 8. 2D-PhC micro-cavity biosensors. (a) Slow light L13 PhC cavity for enhanced 
sensitivity68 ; (b) Nano-holes assisted high sensitivity L13 PhC cavity for plasma protein 
detection of pancreatic cancer60. The Q, S and LOD performances are annotated below 
each picture. Note that there is a trade-off between sensitivity and LOD. 
 
       Our team has extensively described the functionalization of silicon surfaces using 
various probe biomarkers in past research47, 64-66and their use in the detection of specific 
conjugated biomarkers using our silicon photonic crystal microarray structure. Previously, 
we demonstrated a multimode interference coupler architecture shown in Fig. 9a,b also 
shows the series and parallel integration of 64 sensors on the silicon chip. Multiplexed 
sensing with specificity of lung cancer cell line lysates were demonstrated. We have also 
demonstrated experimentally that the silicon photonic crystal sensor chips can be fabricated 
in a commercial foundry for high volume manufacturing. For COVID-19 testing, the silicon 
chip manufacturing process and sensor functionalization process will be the same as before. 
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Fig 9. Integrated sensor array for high throughput detection47, 64-66 (a) Multiplexed 1×4 MMI power splitter 
that splits an input light into 16 optical paths, each with 4 photonic crystal microcavity sensors for 64 sensors 
in total, (b) (top) Microscope image of foundry fabricated silicon photonic crystal sensor devices, (bottom) 
Highly confined electric field in a photonic crystal microcavity for enhanced analyte sensitivity.(c)  
Multiplexed simultaneous specific detection of ZEB1 in lung cancer cell lysates with four arms of the MMI 
derivatized with  bovine serum albumin , isotype matched control mouse IgG1, anti-ZEB1 antibody and  anti-
MYC 9E10 antibody, and (d)  Comprehensive PCW detection platform. 
 
         Label-free microarrays are particularly exciting because it simplifies biochemistry 
significantly when probe-target binding conjugations can be studied without steric hindrance 
associated with fluorescent or radioactive tags. In Fig. 10, we compare our photonic crystal 
microarray approach with other research performed using photonic crystals (PCs) and show 
that our microarray has the highest sensitivity to small changes in concentration.  It summarizes 
sensitivities and detection limits demonstrated in our system compared to other label-free 
methods, including surface plasmon resonance (SPR), opto-fluidic ring resonators (OFRR), 
ring resonator (RR) Pedestal SMGMR and photonic crystal (PC) devices, as function of sensing 
area. Sensitivities of PC microcavity structures demonstrated at Omega Optics (OO) and 
University of Texas (UT), Austin is indicated by UT/OO. 
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Fig 10. Comparison of minimum experimentally demonstrated detection limits versus other label-free optical 
platforms as a function of sensing area on chip. (Legends: PC=photonic crystal47,59,61–66,68,69,84,85,88–92; RR=ring 
resonator69,93–95; SPR=surface plasmon resonance31,96 ; OFRR=opto-fluidic ring resonator97,98, LCR=liquid 
crystal sensors99, BIND=Bio-molecular interaction detection.) UT/OOa has detected 67 pg/ml which is the 
highest sensitivity reported. a UT/OO denoted in the figure is in reference to published works jointly by UT 
Austin and Omega Optics, Inc. 
         Our photonic crystal microcavity not only has high sensitivity and low detection limit, 
but also can achieve dense integration of sensors due to its small geometric size. In Table 1 
below, we compare our proposed PC microarray platform with commercially available bench-
top systems for water monitoring such as inductively coupled plasma mass spectrometry (ICP-
MS) and inductively coupled plasma optical emission spectrometry (ICP-OES, for metals), gas 
chromatography–mass spectrometry (GC-and GC-MS for organics) and ELISA (for all 
analytes with bio-signatures). We compared the technical advantages of our proposed platform 
with other platforms and showed that our platform can provide comparable sensitivity to 
existing desktop systems, while also being portable. 
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Table 1. Summary of technical advantages of our work  vs commercialized approaches 90–93,95–97,99–101 59,60,63,68,69,102. 
 
 
III. PLASMONIC OPTICAL BIOSENSORS 
A plasmon can be described as a collective oscillation of a free electron or a quantum of plasma 
oscillation. Propagation of electromagnetic waves along the surface of a metallic surface or 
surface plasmons (SP) can be understood as a strong interaction between conduction electrons 
of the metallic surface and electromagnetic waves, which leads to resonance modes trapped on 
the surface, also known as surface plasmon resonances (SPRs)31,44,45. SPR propagation along 
the conductor surface produces a charge density distribution, which enhances the light matter 
interaction on the nanoscale. Such enhancements, so called “hot spots”, occurred at the 
interface between a dielectric and metallic surface offer the higher sensitivity for plasmonic 
biosensors. Many types of optical biosensors based on plasmonic platforms have been studied 
as fascinating candidates for biomedical and chemical sensors 28,29,46,103–113.  The selectivity of 
the plasmonic-based biosensor can be achieved by using immobilization of the various 
bioreceptors; depending on the target analytes, specific bioreceptors can be selected to be 
immobilized on the surface of the sensor and react or bind only to its counterparts. Based on 
the device configurations, plasmonic biosensors can be divided into two groups, SPRs and 
localized SPRs (LSPRs). 
A. Surface plasmonic resonance (SPR) sensor 
Fundamentally, when the phase matching condition between the incident light and the 
SP wave guided along the metal/dielectric interface is reached, the incident light can be coupled 
to the surface guided mode. Note that the resonance condition between the incident light and 
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the conductive electrons at the metal/dielectric interface with a fixed angle of incidence is only 
achieved at a specific wavelength. The guided light will be absorbed by the conducting 
electrons that resonates, which will significantly reduce the reflected light at that particular 
wavelength. Therefore, once the target molecule is attached to the functionalized metal film, 
the refractive index does change, causing a shift in the resonance wavelength. Consequently, 
SPR angle alteration can be characterized as the main sensing mechanism. Several coupling 
methods have been proposed, including a grating coupler, a waveguide coupler, and a prism 
coupler, but the prism coupling method has been used as a standard configuration based on the 
Kreichman configuration114. Figure 11. shows the schematic of the conventional SPR sensor 
configuration. 
 
Fig 11. The schematic illustrations of the standard SPR based biosensor configuration. 
 
The wavevector of the evanescent field of the incident electromagnetic wave 
propagating along the prism-metal interface is shown in the following equation115,116 : 
𝑘𝑖𝑛 =
2𝜋
𝜆
𝑛𝑝sin (𝜃)              (8) 
where 𝑛𝑝 is the refractive index of the prism, 𝜆 is the wavelength of the incident light, 𝜃 is the 
incident angle. The wavevector of the SP wave propagating along the metal/dielectric interface 
is as below116,117 : 
𝑘𝑆𝑃 =
𝜔
𝑐
√
𝑛𝐷2𝑛𝑀2
𝑛𝐷2+𝑛𝑀2
     (9) 
where 𝜔 is the angular frequency of the wave, c is the speed of light in vacuum, 𝑛𝑀 and 𝑛𝐷 are 
the refractive indices of the metal and dielectric. As aforementioned, the resonance condition 
is met when 𝑘𝑖𝑛 = 𝑘𝑆𝑃, so we can calculate the SPR angle in the following equation: 
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𝜃𝑆𝑃𝑅 = 𝑠𝑖𝑛
−1(
1
𝑛𝑝
√
𝑛𝐷2𝑛𝑀2
𝑛𝐷2+𝑛𝑀2
)                                            (10) 
The sensitivity of the SPR devices are determined by the resonance shift with respect to the 
change of the refractive in the absence and presence of the target analyte 118–122: 
S=
Δ𝜆
Δ𝑛
       (11) 
where Δ𝜆 is the resonance wavelength shift and Δ𝑛 is the change of bulk refractive index 
including the target analyte. 
B. Localized SPR sensor 
On the other hand, nanostructures in conductive thin films are among the essential 
building blocks of LSPR plasmonic biosensors (see Fig.12). These nanoscale 
geometric/periodic lattice factors bring huge advantages over conventional SPR devices. 
Contrasted with SPR occurring along the propagation surface, the attenuation length of the 
local electromagnetic field is much shorter. These strict restrictions, with a shorter sub-
wavelength structure, can achieve ultra-low mode volume resonance, making it sensitive to 
environmental refractive index changes, which are particularly helpful for the detection of tiny 
biological molecules. Also, an incident light can be directly coupled to SP wave on the 
conductive structures without any external couplers, e.g., prism or gratings, which ameliorates 
the complexity of the entire system and enables the sensor miniaturization123 and the 
absorbance, transmittance, and reflectance-based sensing42,107–109,124–126.  
 
Fig 12. The schematic illustration of the resonance wavelength shift sensing based LSPR sensor configuration. 
Moreover, LSPRs can be utilized for various types of resonance modes and detection 
methods, including surface-enhanced Raman spectroscopy (SER)28,112, photo-
luminescence/fluorescence50,111, and mid-infrared spectroscopy106, by tuning the resonance 
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wavelength for a specific light-matter interaction. Table 2 shows the comprehensive 
comparison between the conventional SPR and LSRP biosensors. 
 
Table 2. The comparison between SPR and LSPR sensors. 
 
 
1. Resonance shift sensing 
Figure 12 shows the basic configuration of the LSPR device based on the resonance 
shift sensing. The metal nanostructure on the dielectric substrate is used as a resonator, and due 
to the above-mentioned advantages, the sensitivity can be further improved compared with the 
conventional SPR resonance shift device. The sensitivity and the figure of merit of LSPR 
resonance shift sensors follows the same definition of SPR’s as in eq. (11). Another important 
performance factor of resonance-based sensor is the quality factor (Q), which is defined as 
127,128 : 
𝑄 =
𝜆𝑜
𝐹𝑊𝐻𝑀
            (12) 
where 𝜆𝑜 and FWHM are the wavelength and full-width half maximum of the resonance peak, 
respectively. To enhance the sensing performance, a higher Q value is desirable because of the 
reason that sharper peaks with high Q values are much easier to detect. Considering all these 
factors, the inherent detection limit (ILOD) of the resonance displacement sensing device can 
be defined as follows80,129 : 
ILOD =
𝜆𝑜
𝑄∙S
              (13) 
which indicates that both the higher sensitivity (S) and Q factor are required to minimize the 
limit of detection of the sensors.  
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Although these so-called hot spots provide higher sensitivity for LSPR biosensors, their 
performance is greatly limited due to the basic limiting factors of ohmic losses in metal 
surfaces. In other words, compared to other photonic biosensors, the absorption loss in the 
conductive nanocavity leads to a low Q value, so research has been conducted to achieve low-
loss devices by using advanced materials or optimizing the geometry of metamaterials. 
 
2. Plasmonic perfect absorber 
 
Fig 13. The schematic illustration of LSPR perfect absorber-based sensor. 
On the other hand, the concept of a plasma perfect absorber (PPA) sensor was 
introduced to overcome this intrinsic limiting factor130–134. Figure 13 shows the typical 
configuration of PPA sensor consists of periodically arranged metallic nano antennas 
(metamaterial) on top and thin metallic ‘mirror’ layer on the bottom separated by dielectric 
spacer132. The basic concept is to have a perfect absorbance at the operating wavelength and 
make a ‘zero’ transmittance by maximizing the metamaterial losses; in other words, the losses 
are served as an advantage in the PPA sensors. In this structure, most of the incident light at 
the operating wavelength is absorbed by top nano antennas operating as a resonator through 
impedance matching, and the metallic bottom layer act as a ‘mirror’ to eliminate the 
transmittance. As a result, the reflectance of light can be characterized for sensing as in figure 
13, and the figure of merit (FOM𝑃𝑃𝐴) is defined as below
133 : 
𝐹𝑂𝑀𝑃𝑃𝐴=|
𝑑𝐼(𝜆𝑜)/𝐼(𝜆𝑜)
𝑑𝑛(𝜆𝑜).
|              (14) 
where 𝑑𝐼(𝜆𝑜)/𝐼(𝜆𝑜) is the relative intensity change of reflected light at a fixed resonance 
wavelength 𝜆𝑜, which is induced by a refractive index change 𝑑𝑛(𝜆𝑜).  
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Moreover, it has been shown that the perfect absorption (>99%) of incident light at 
working wavelength can be remained over a wide incident angle and insensitive to the 
polarization (TE/TM) of incident light133.  
3. Surface-enhanced infrared absorption spectroscopy 
 
Fig 14. The Intensity change of transmitted light based LSPR sensor; typically adapted for mid-infrared absorption 
spectroscopy.  
Another important detecting method using LSPR is surface-enhanced infrared 
absorption (SEIRA) spectroscopy. Based on the molecular absorption spectroscopy and the 
fundamental vibrational-rotational transitions of chemical bonds in the wavelength of 3 - 20𝜇𝑚, 
mid-infrared (MIR) absorption spectroscopy has been studied vigorously for the label-free 
detection and identification of molecules in the optical sensor domain. Especially, unlike the 
near infrared wavelength region, the molecular fingerprint region (700−1500 cm−1) in MIR 
wavelengths contains many absorption bands related to bending and stretching of chemical 
bonds (such as −C−C−, −C−O−, −C−N−, etc.) that allow the unique identification of 
biomolecules with high sensitivity and specificity.  
Amongst many types of optical based molecular absorption spectroscopy platforms, 
SEIRA spectroscopy for LSPR devices has been shown its great promise for detecting thin 
layer of surface-bound nano-molecules due to its tight confinement of surface plasmons on 
metallic nanostructures, which can significantly enhance the IR absorption of small molecules. 
Figure 14 shows the typical configuration of SEIRA spectroscopy using LSPR sensor. When 
the plasmonic resonance peak generated by the metallic nano-antennas is matched with the 
fundamental vibration signatures of chemical bonds in the biomolecules, the coupling of 
molecular transitions with the LSPR field on the surface makes significant absorption of 
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corresponding wavelength, so the decrease of transmitted light can be characterized as a 
sensing result. To obtain more intense IR absorbance, researches have shown various 
nanostructures including nanorod antenna 135, coaxial-nanogaps136, and nano cavities137–139 to 
enhance the optical confinement and field enhancement of MIR light. 
 
Taking all these device structures and detection methods into account, a number of 
nanostructure designs have been studied and optimized to apply the plasmonic resonance 
sensor for the label-free real time detection of various bio-analytes. As shown in Fig. 15a, Lee 
et al. have shown a multiplex biosensor for cancer biomarkers detection based on the resonance 
shift of LSPR single gold nanoparticles; the selective sensing results with LOD of 91 fM, 94 
fM and 10fM for the α-fetoprotein (AFP), carcino embryonic antigen (CEA) and prostate 
specific antigen (PSA) analytes are reported by antibody-antigen binding42. Amanda et al. 
reported the detection of Alzhimer disease biomarkers from clinical samples as shown in Fig. 
15b; Using surface-confined Ag nanoparticles and sandwich assay, the LOD of < 100 fM for 
amyloid-â derived diffusible ligands (ADDLs) detection with the specific anti-ADDL 
antibodies is reported by LSPR induced wavelength shift 109. To increase the refractive index 
sensing of LSPR, plasmonic gold mushroom arrays were introduced approaching the 
theoretical limit of standard SPR configuration with gold surface by Yang et al.; Fig. 15c shows 
the schematic structure and SEM images of gold mushroom arrays with the detection result of 
cytochrome c and alpha-fetoprotein, with their LOD down to 200 pM and 15 ng/mL, 
respectively140. Pengyu et al. reported the multiplex serum cytokine analysis by immunoassay 
enhanced using nano-plasmonic biosensor microarrays (Fig. 15d). Periodically arranged gold 
nanorod microarray conjugated with corresponding antibodies of each cytokine species (IL-2, 
IL-4, IL-6, IL-10, IFN-γ, and TNF-R) results in LOD of 5-20 pg/mL from a 1 μL serum sample 
within 40 min124. The hemagglutinin (HA) proteins derived from avian influenza virus 
detection using SPR device was also reported from Emi et al., with 3.125 nM LOD as shown 
in Fig. 15e141. Recently, Daehan et al. reported the SEIRA spectroscopy using an array of 
coaxial nano-apertures resonators reported a strong IR absorption enhancement factor of 
104~105 , and observed ~58 % suppressing of transmitted IR signals from 5nm thick silk 
protein film as shown in Fig. 15f 136. Infrared PPA sensor has been reported as in Fig. 15g; Na 
et al. reported experimental demonstration of Infrared PPA sensor with 99% absorbance at the 
wavelength of 1.6 𝜇𝑚, and 𝐹𝑂𝑀𝑃𝑃𝐴 (eq. (15)) of 87, and 400 nm/RIU sensing sensitivity from 
glucose solution133.Intgeration of graphene with SPR sensor as reported by Shuwen et al. have 
shown an ultrasensitive sensing (Fig. 15i); they reported the LOD of 1 aM for 7.3 kDa 24-mer 
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single-stranded DNA142. Moreover, ultrasensitive SPR sensor based on halloysite nanotubes 
(HNTs)/MoS2/black phosphorous(BP) atomic layers on gold films have been introduced by 
Guang et al., with the angular and phase detection sensitivities up to SA = 77.1 RIU
-1 and SP = 
1.61×105 RIU-1, respectively143. 
 
Fig 15. Various SPR and LSPR bio sensing applications. (a) Multiplex biosensor for cancer biomarkers detection 
based on the resonance shift of LSPR single gold nanoparticles; LOD of 91 fM, 94 fM and 10fM for AFP, CEA 
and PSA, respectively42. (b) Alzheimer disease biomarkers from clinical samples using surface-confined Ag 
nanoparticles and sandwich assay; LOD of < 100 fM for ADDLs109. (c) Plasmonic gold mushroom arrays with 
the LOD down to 200 pM and 15 ng/mL for Cyt c and AFP detecting, respectively140. (d) Multiplex serum 
cytokine immunoassay using gold nanorod microarray conjugated with antibodies to detect cytokine species124. 
(e) Avian influenza virus detection using SPR device with 3.125 nM LOD141. (f) Coaxial nano-apertures array 
resonators for SEIRA spectroscopy with IR absorption enhancement factor of 104~105, achieving ~58 % 
suppressing of transmitted IR signals from 5nm thick silk protein film136. (g) Infrared PPA sensor with 99% 
absorbance at the wavelength of 1.6 𝜇𝑚, FOM of 87, and 400 nm/RIU sensing sensitivity from glucose solution133 
. (h) Ultrasensitive graphene-gold metasurface SPR sensor with LOD of 1 aM for 7.3 kDa 24-mer ssDNA142. (i) 
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Ultrasensitive SPR sensor based on halloysite nanotubes/MoS2/black phosphorous hybrid surface with SA = 77.1 
RIU-1 and SP = 1.61× 105 RIU-1. 143 
4. SARS-CoV-2 sensing Application  
Here, we review the most up-to-date advances, especially for the coronavirus sensors 
in plasmonic domain, and introduce well-established plasmonic SARS-CoV-2 biosensing 
systems. Researchers have demonstrated that using SPR/LSPR-based sensors and 
corresponding binding biological receptors can effectively and selectively detect 
coronavirus103,105,113 (Table 3). Moreover, several researches have already reported SARS-
CoV-2 sensing results as in figure 16 29,126. 
Table 3. Summary of applications of various plasmonic biosensors for Coronavirus family. 
 
 
 
Fig 16. State-of-the-art plasmonic biosensor for SARS-CoV-2 sensing applications. (a) Photothermal enhanced 
LSPR biosensor for nucleic acid sequences detection from SARS-CoV-2. The schematic shows the configuration 
of LSPR device consists of gold nanoparticles where the local heat is generated by the thermo-plasmonic effect. 
The graph shows the sensing enhancement by the thermal excitation with the limit of detection of 0.22 pM and 
the sensing selectivity between the RdRp-SARS and RdRp-COVID hybridization; Reprinted from29. (b) SARS-
CoV-2 antibodies sensing with SPR in undiluted human serum. The schematic shows the SPR device 
   
 
   
 
31 
configuration, coated with a peptide monolayer to detect SARS-CoV-2 antibodies, and the graphs show the 
sensor-gram and SPR sensing results with the limit of detection value of 100 ng 𝑚𝐿−1; Reprinted from126. 
 
A recent article reported the dual-functional plasmonic photothermal biosensors for 
SARS-CoV-2 detection29. The authors demonstrated a highly sensitive, fast, and reliable 
SARS-CoV-2 virus detection capability by integrating the plasmonic photothermal (PPT) 
effect and conventional LSPR sensing transduction on a single gold nanoislands (AuNI) chip. 
The two-dimensional AuNIs functionalized with cDNA receptors (RdRp-COVID-C) can 
perform a selective detection of the RdRp-COVID through DNA hybridization, and the LOD 
down to the concentration of 0.22 pM is reported. Lately, Djaileb et al reported the antibody 
detection specific against SARS-CoV-2 in undiluted human serum using SPR sensing126. A 
SPR sensor coated with a peptide monolayer detected anti-SARS-CoV-2 antibodies in the 
nanomolar range (LOD of 100 ng 𝑚𝐿−1) was performed and analyzed within 15 minutes.  
Furthermore, several researches reported that the sensitivity and the signal-to-noise 
ratio (SNR) of conventional enzyme-linked immunosorbent assay (ELISA) or fluorescence-
linked immunosorbent assays (FLISA) tests can be significantly improved by applying the 
‘add-on’ plasmonic particles without altering their workflow50,103. As the ELISA test is widely 
used for precise SARS-CoV-2 detection103, plasmon enhanced ELISA/FLISA tests can be 
applied to COVID-19 sensing as well. 
Although aforementioned SARS-CoV-2 sensing applications29,126 have shown great 
performances of sensitive and selective sensing, a huge potential for more sensitive, accurate 
and fast on-chip sensing with less complex system is still remained in LSPR biosensor domain. 
For example, the sensing systems in Fig. 1629,126 require the prism coupler to couple the 
incident light into SPR device with an accurate incident angle. It requires very sensitive 
alignment of optical devices which makes the overall system complex and hard to be integrated 
with sources and detectors. However, as described earlier in Table. 2, the incident light can be 
coupled into LSPR sensors directly without the external couplers, and this normal-incident 
angle can make the alignment easier, in turn mitigate the complexity of the system and make 
the possibility of fully integrated on-chip sensing; moreover, due to the capability of sensor 
miniaturization through LSPR nanostructures, label-free, real-time, and parallel detection with 
multiple channels with high-specificity are achievable. Furthermore, improving the sensitivity 
by applying advanced materials has incited a great interest for various optical biosensor 
applications. For plasmonic biosensors, the ultrasensitive graphene and 2D material enhanced 
SPR devices have been reported as shown in Fig. 16 (h) and (i)142,143, and the experimental 
sensing result with LOD value approaching 1 atto M has been shown142,144. Accordingly, the 
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advanced material enhanced LSPR biosensors are anticipated to enable the possibility of highly 
sensitive, accurate and fast point of care lab-on-a-chip integrated sensor with unprecedented 
high sensitivity. The detailed discussion of emerging nanomaterials for optical biosensors are 
described in section V. 
IV. SARS-COV-2 BIOSENSOR: DESIGN AND IMPLEMENTATION 
To develop an accurate estimate of COVID-19 biosensing functioning mechanism, a 
simulation model need to be first designed. Here, in a proposed simulation model, COVID-19 
is approximated to be a solid sphere core containing RNA covered with a membrane protein 
with radiuses of r1 and r2, respectively (Fig. 17a)
45. Thus, the effective RI of the virus is 
calculated by taking a volume weighted sum of the two refractive indices: 
   (x) 
where n1 (V1) and n2 (V2) are the total RI of the RNA and the membrane protein volume, 
respectively. As the RI of the virus is determined mainly by material composition rather than 
its geometrical size, η is a constant value for the same kind of virions.  (ηCOVID-19 =1.25 average 
value of several measurements of transmission electron microscopy (TEM) pictures145). We 
use the SWGR design to simultaneously take advantage of the enhanced binding surface and 
strong light-substance interaction. As shown in Fig. 17 c and e, the energy mode is distributed 
between the gratings as well.  In order to further improve the SWG waveguide functioning in 
the sub-wavelength range, the grating period Λ, the waveguide width w, and the fill factor are 
designed to be 230nm, 1.23μm, and 0.5μm, respectively. For the SWGR, the radius R is set as 
5μm with the corresponding FSR57 of 25nm at 1550nm. Here simulation system includes a 
220nm-Silicon top-layer with a 3μm buried oxide (BOX) wafer and a liquid solution, with the 
refractive index of nclad to be 1.35
31. Adopting our previous designs features38,39, we optimized 
a high-Q SWGRs by utilizing a trapezoidal (T) silicon pillars and reducing bending loss by 
~50% compared to a conventional rectangular silicon pillar. We therefore set the SW 
waveguide width to be 0.5µm (correlated to the fundamental mode of transverse electric (TE)) 
and studied the effect of the trapezoidal width. It is noted that to obtain the lowest bending loss 
of the T-SWG waveguide, we employ the particle swarm method for the optimization process.  
Three parameters (w, A1, A2) are optimized and are defined as the width, the tuning factor of 
the outer and inner filling factor of the SWG, respectively (as shown in the inset figure of Fig. 
17b). Considering the limitations of the design for fabrication, the slot between gratings are 
pre-set to be larger than 60nm, thus A1 and A2 are limited to be (1, 2) and (0, (1-60nm/Λ)/f), 
3
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respectively. At the same time, to keep the SWG working in subwavelength regime (Λ<< 
𝝀/2neff), Λ is safely set to be 230nm and f is simply set to be 0.5 with no optimization. 
Furthermore, to make the SWG waveguide work as a single or few mode waveguide, the width 
of the gratings is set less than 2μm. All in all, the ranges of w, A1, and A2 are set to be (0.5μm, 
2μm), (1,2), and (0, 0.522), respectively. The FOM is defined to achieve the lowest bending 
loss with the bend radius of 5μm. Based on the optimization measures taken, we finally 
achieved a bending loss as low as 0.0279 dB/cm with the optimized (w, A1, A2) = (1.23µm, 1, 
0.522). By adjusting the coupling gap between the insertion SWG waveguide and the designed 
SWGR, the Q can be as high as ~50000 (the resonance at 1557.6nm) with a broad FSR of 25 
nm, as shown in Fig. 17a. We also optimized the 10µm radius SWGR (not shown in the Fig.17f, 
achieving a loaded Q of ~75000 (the resonance at 1552.1nm) with the FSR of 11nm with (w, 
A1, A2) = (1.23µm, 1, 0.522), at the same waveguide-ring cross-coupling coefficients. Needless 
to say as quality factor of the ring becomes higher, the fabrication tends to be more challenging. 
Bulk RI sensitivity (shown in the Fig.11f inset figure) in the buffer solution is calculated to be 
𝑆𝑟𝑒𝑠 =
𝛥𝜆𝑟𝑒𝑠
𝛥𝑛𝑐𝑙𝑎𝑑
= 400 𝑛𝑚/𝑅𝐼𝑈. Thus the iDL can be calculated as low as ~7.5e-5 RIU. Note that 
iDL performances can be further improved by exploiting a larger radius ring or by further 
achieving the critical coupling condition given the predictable higher Q, while making trade-
off between the performance and the sensor size or the resonance peak extinction ratio. 
Surface sensing: To evaluate the specific sensing ability of the proposed device for COVID-
19, surface sensing performances are analysed by considering the device immersed in buffer 
solution, bonded by several surface layers (generated in the sensing preparation process) 
including the ~2-3nm surface oxide layer, ~10nm functionalization layer and bonded antibody 
(protein layers), and the bonded virus particles layer in detection process. In simulations, the 
preparation process generated layers are further simplified to be a uniform layer (RI: 1.45) with 
a thickness of 15nm, and the bonded virus layer is simplified as a uniform layer with a thickness 
of 125nm (the maximum diameter of the COVID-19 virus) (Fig. 17a). It is noted that the 
equivalent RI of the virus layer (nbinding) depends on the number of bonded virus, which is a 
function of the virus concentration and binding processing time, and is dominated by the 
concentration in real sensing process with a given binding time. Thus, the SWGR sensing 
performance can be evaluated by calculating the nbinding response of the device, with the nbinding 
ranging from 1.35 (no binding) to 1.5 (full binding). Simulation results in Fig.17f shows the 
functionalization and the full binding process induces a shift of 3.41nm and 1.14, respectively. 
The obvious simultaneous measurable shifts in the FSR range (𝛥𝜆𝑟𝑒𝑠 < 𝐹𝑆𝑅) and experimental 
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values (𝛥𝜆𝑟𝑒𝑠 ≫ 1𝑝𝑚) indicates the promising potentials of the proposed device in detecting 
the COVID-19 virus or simply being as a chemical/bio-sensor in future practical applications. 
 
Fig. 17 (a) Schematic the COVID-19 virus, (b). Schematic illustration of the SWGR biosensor with a low loss 
in/out coupling via lineally tapering the input and the output gratings, (c) Top view of the simulated SWGR 
biosensor for a fundamental TE mode at 1550nm, (d)  Details of the bonded COVID-19 on the substrate, (e) 
Simulated intensity distribution of the electric field at 1550nm. Light penetrates between the slot waveguides 
providing better light matter interaction with the COVID-19 analyte, and (f) Calculated transmission spectrum of 
the proposed device. Inset figure shows the calculated bulk RI sensing and surface sensing responses of the device, 
with the bulk RI sensing shows a sensitivity of 400nm/RIU, and surface sensing shows the total wavelength shifts 
of 3.41nm nm and 1.14 nm after the functionalization process and the full binding process, respectively. 
V. TWO-DIMENSIONAL MATERIALS OPTICAL BIOSENSORS  
      Latest major advancements in preparation, development, and utilization of new low-
dimensional materials has been attractive for development of modern miniaturized biosensors 
and immunosensors.  Graphene and its analogous 2D materials such as transition metal 
dichalcogenides (TMDCs), carbides and nitrides(Mxenes), hexagonal boron nitride (h-BN), 
black phosphorus (BP) and transition metal oxides (TMOs) have attracted great attention to be 
used as transducer due to combined high sensitivity and selectivity for biosensors.   
A. Graphene and graphene oxide (Gr and GO) 
       Graphene has been regarded a revolutionary material ever-since its first introduction in 
2004146, given its extraordinary optical and electronic properties 32,147–161.  Since then, graphene 
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has also shown an immense potential in different applications and a great deal of graphene 
based biomolecular sensors have been specifically developed by paying especial attention to 
its biocompatibility and high specific surface area45,162–164 .  On top of that, unique and ideal 
optical properties such as broadband and tunable absorption and polarization-dependent 
nonlinear optical effects make graphene a promising candidate to be employed for optical 
based biosensors (Fig 18).  The introduction of advanced biosensors through graphene 
electrical and optical qualities in general has delivered extraordinary sensitivity, detection 
level, resolution and response time in many devices (Fig 18. c and d)32,106,151,152,154,163–167.   
Point-of-Care biosensors has also shown enhanced sensitivity in graphene based 
electrochemical biosensors as well168.  While pristine graphene has seen applications in 
biosensors devices, its derivative GO has been subjected to a wealth of investigation for 
rapid detection, disinfection of pathogens and enzyme assays, making it a key material for 
a variety of biomedical applications. Graphene oxide has been a suitable precursor for 
graphene and its biosensors applications especially due to its attractive distinctive properties 
like good water dispersibility, facile surface modification and to be more specific photo-
luminescence for optical biosensors. Jin et al demonstrated a functionalized graphene oxide 
wrapped around SiO2 which possess superior RNA sensitivity and limit of detection up to 1 
fM with the potential to show even higher sensitivity values169.  They showed the high electron 
conduction and higher surface area in spherical morphology has been specially effective to 
improve the sensitivity and limit of detection169.  Graphene unique electrical properties has also 
been exploited effectively to develop different transistor based label-free biosensors including 
COVID-19 detection system39 (fig 18.a).  Aside from the field-effect-transistor-based graphene 
biosensor, which relies mainly on current changes, providing easier mass-scale production with 
satisfying sensitivity, it’s limited sensing capability along with being damaging to living cells 
make its application limited compared to analogous optical ones170 [Table 3].  
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Fig 18. a) Schematic of functionalized graphene FET immunosensor. Inset shows the effect of 
functionalization with CSAb vs non-functionalized graphene on increasing sensitivity to COVID-19 
antibodies spike protein39. b) The band structure of graphene under different gate voltages of positive, almost 
zero and negative from left to right, respectively. (c) (left) Three-dimensional representation of a graphene 
photodetector154 (right) Cross-sectional schematic of the device, where the Ti/Au metallic structures are in 
close proximity to each other for forming the plasmonic slot waveguide d) Measured responsivity vs bias 
voltage of graphene photodetector. Inset shows a broadband responsivity from 1300 to 1400 nm. The spectral 
response of the graphene-slot detector is mainly limited by the relatively narrow metallic grating coupler 
operating bandwidth.  
 
The interaction of graphene with light is a determining factor in effectiveness of 
integrated graphene with different photonic and optoelectronic devices including 
biosensors; a high-quality graphene-based biosensor requires a strong interaction between 
graphene and light. An undoped graphene monolayer has a constant broadband absorption 
equal to %2.3171. It has been shown that the Fermi level of graphene can be tuned by either 
electrical or chemical dopant beyond half of the photon energy156,172,173 (Fig 18) which is 
critical for sensitivity enhancement in a graphene based label-free biosensor. This happens 
as a result of graphene becoming transparent due to Pauli blocking effect. This in turn leads 
to significant refractive index change (RI) and phase shift of the input light. High 
nonlinearity in graphene opens the door to a broad range of graphene based nonlinear 
plasmonic sensor applications174.  
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B. Graphene Surface Plasmon Resonance  
Researchers have investigated plentiful ways of enhancing the sensitivity of the SPR 
sensor, including but not limited to the use of resonant structures such as metal nanoparticles 
and optical gratings.  As shown before, in a typical SPR or LSPR biosensor, a thin metallic 
film like Ag or Au gets deposited on prism to separate it from the sensing area. The deposited 
metallic film brings out the propagation of surface plasmon at visible light frequency. Gold 
is preferred as it provides better resistance to oxidation and corrosion in different 
environments.  The intrinsic defects in gold and silver-based biosensors like oxidization of 
metal, poor adsorption to biomolecules and hence limited sensitivity and accuracy leads 
researchers to seek methods of alternatives.  In view of the defects of biosensors based on 
gold and silver film, graphene-based biosensor has been developed.  Graphene provides a 
highly sensitive non-oxidizing receptor substrate to analytes152,166,175.  Moreover, graphene 
also helps to adsorb biomolecules better, because of π-π stacking, which increases the 
system’s affinity for these molecules (Fig 19) 
 
 
Fig 19. a) Schematic of the surface plasmon resonance(SPR) enhanced with graphene layer [adapted 45] and b) 
Schematic of a SPR biosensor functioning mechanism(Reprinted44). 
 
Table 3. The difference between a graphene-based electrical and optical sensor [adapted32,155,156]. 
Sensor type Working principle Advantages Disadvantages 
Graphene electrical sensor Ambipolar behaviour of the graphene and its 
doping by applying gate voltage enables 
sensing by induced changes in drain-source 
conductivity of the graphene channel upon the 
binding of the sample to the receptor-
functionalized graphene 
Small size, fast electron 
transfer and response time, 
high sensitivity and reduced 
surface contamination 
Limited sensing capacity (only current 
changes), low spatial resolution, 
damaged testing sample 
Graphene optical sensor Enhanced polarization absorption and 
broadband absorption under total reflection 
enables sensing by using attenuated total 
reflection to detect refractive index changes 
near the surface 
High spatial resolution, 
wide detection range, high 
sensitivity and precision, 
accurate and fast detection, 
unlabeled samples 
Photocurrent is too small due to low 
absorption rate of graphene 
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The graphene plasmonic nano-islands can demonstrate nonlinearities two orders of 
magnitude higher than the their non-graphene counterparts of equal size174.  These nano-
islands can be used as nonlinear plasmonic biosensors, as the presence of an individual 
molecule is sufficient to trigger a large change in the nonlinear response of the graphene 
plasmons.  The effect of functionalization on the sensitivity enhancement of graphene and 
using it especially for biosensors have been discussed in detail29,176–179.        
 
C. Transition metal dichalcogenides (TMDCs) 
Transition metal dichalcogenides(TMDs) are a class of materials including but not limited 
to MoS2, MoTe2 and TiNb. Bulk crystals of TMDs have been long known to researchers 
throughout the world but the new discoveries in isolation of their two-dimensional(2D) 
structures has led to a plethora of new properties Unique physical and chemical properties 
of 2D TMDs including high surface to volume ratio, sizable bandgap and high absorption 
coefficient along with high potential for redox reactions on its surface makes them capable 
of superior molecular sensitivity180. 
MoS2 has recently found widespread applications as a fluorescence probe in the detection 
of various biological and environmental analytes. As discussed in the previous section, 
MoS2 possesses good optical properties like fluorescence and have been utilized to design 
various sensing devices. The possession of PL characteristics provides the possibility of 
using such structures in fluorescence-based applications, which can be used to trace, image, 
and sense biological components. The Raman characteristics of the MoS2 monolayer is also 
a function of the dimension and permittivity of the environment. Attaching biological 
components may alter such characteristics and thus can be used as a biosensing principle.  
VI. CONCLUSION  
Emerging pandemics and epidemic diseases like COVID-19 brings out a high demand in 
advancement and research in medical detection and treatment methods. The optical 
biosensors provide a fast detection (< 1min) of such a virus at very low concentrations (~1 
fM). However, they need to be designed and functionalized to be the most absorptive to the 
target analyte.  The ideal label-free biosensor is cheap, disposable, or reusable, compact, 
and semi-automatic.  Although most efforts in biosensors have been focused on protein 
biomarkers, other targets such as small molecules and nucleic acids are crucial in expanding 
the application of biosensors including optical ones.  A common challenge for optical 
   
 
   
 
39 
biosensors is to reach the capability of performing the measurement in real complex 
samples, avoiding, or limiting the sample preparation phase. Developing label -free 
biosensor is aligned with that purpose as the need for on-site detection techniques is boosting 
as the world post-COVID-19 pandemic will never be like before.  
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